Rawlins, MD, Culyer, AJ. National Institute for Clinical Excellence and its value judgments. BMJ
2004; 329: 224–7.
Becker, M, Diamond, R. Quality of life measurement in persons with schizophrenia: are we measuring what's important. In Quality of Life in Mental Disorders, 2nd edn (eds Katschnig, H, Freeman, H & Sartorius, N). John Wiley & Sons, 2006.
Herrman, H, Hawthorne, G, Thomas, R. Quality of life assessment in people living with psychosis. Soc Psychiatry Psychiatr Epidemiol
2002; 37: 510–8.
Meijer, CJ, Koeter, MW, Sprangers, MA, Schene, AH. Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol
2009; 44: 361–8.
Narvaez, JM, Twamley, EW, McKibbin, CL, Heaton, RK, Patterson, TL. Subjective and objective quality of life in schizophrenia. Schizophr Res
2008; 98: 201–8.
Wittchen, HU, Lachner, G, Wunderlich, U, Pfister, H. Test-retest reliability of the computerized DSM–IV version of the Munich-Composite International Diagnostic Interview (M–CIDI). Soc Psychiatry Psychiatr Epidemiol
1998; 33: 568–78.
Perälä, J, Suvisaari, J, Saarni, SI, Kuoppasalmi, K, Isometsä, E, Pirkola, S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry
2007; 64: 19–28.
First, MB, Anthony, JC, Tepper, S, Dryman, A. Structured Clinical Interview for DSM–IV Axis I Disorders, Research Version, Non-patient Edition (SCID–I/NP). Biometrics Research, New York State Psychiatric Institute, 1997.
Tengs, TO, Wallace, A. One thousand health-related quality-of-life estimates. Med Care
2000; 38: 583–637.
Saarni, SI, Härkänen, T, Sintonen, H, Suvisaari, J, Koskinen, S, Aromaa, A, et al. The Impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res
2006; 15: 1403–14.
The EuroQoL Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy
1990; 16: 199–208.
Sintonen, H. The 15D Measure of Health Related Quality of Life: Reliability, Validity and Sensitivity of its Health State Descriptive System. Working Paper 41. Centre for Health Program Evaluation, Monash University, 1994.
Dolan, P. The measurement of health-related quality of life for use in resource allocation desicions in health care. In Handbook of Health Economics (eds Culyer, AJ & Newhouse, JP): 1723–60. Elsevier, 2000.
Sintonen, H. The 15D Measure of Health Related Quality of Life. II Feasibility, Reliability and Validity of its Valuation System. Working Paper 42. Centre for Health Program Evaluation, Monash University, 1995.
Sintonen, H. The 15D instrument of health-related quality of life: properties and applications. Ann Med
2001; 33: 328–36.
Brooks, R. EuroQol: the current state of play. Health Policy
1996; 37: 53–72.
Rabin, R, de Charro, F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med
2001; 33: 337–40.
Kind, P, Hardman, G, Macran, S. UK Population Norms for EQ-5D. Discussion Paper 172. Centre for Health Economics, University of York, 1999.
Walters, SJ, Brazier, JE. Comparison of the minimally important difference for two health state utility measures: EQ–5D and SF–6D. Qual Life Res
2005; 14: 1523–32.
Hawthorne, G, Richardson, J, Day, NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med
2001; 33: 358–70.
Stavem, K, Bjornaes, H, Lossius, MI. Properties of the 15D and EQ-5D utility measures in a community sample of people with epilepsy. Epilepsy Res
2001; 44: 179–89.
Garratt, A, Schmidt, L, Mackintosh, A, Fitzpatrick, R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ
2002; 324: 1417.
OECD. The OECD List of Social Indicators. Organisation for Economic Co-operation and Development, 1982.
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry
1961; 4: 561–71.
Kendler, KS, Karkowski, LM, Walsh, D. The structure of psychosis: latent class analysis of probands from the Roscommon Family Study. Arch Gen Psychiatry
1998; 55: 492–9.
Kendler, KS, McGuire, M, Gruenberg, AM, O'Hare, A, Spellman, M, Walsh, D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry
1993; 50: 527–40.
Andreasen, NC. The Scale for the Assessment of Positive Symptoms (SAPS). The University of Iowa, 1984.
Andreasen, NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982; 39: 784–8.
Suvisaari, J, Perälä, J, Saarni, SI, Juvonen, H, Tuulio-Henriksson, A, Lönnqvist, J. The epidemiology and descriptive and predictive validity of DSM-IV delusional disorder and subtypes of schizophrenia. Clin Schizophr Relat Psychoses
2009; 2: 289–97.
Austin, PC, Escobar, M, Kopec, JA. The use of the Tobit model for analyzing measures of health status. Qual Life Res
2000; 9: 901–10.
Tobin, J. Estimation of relationships for limited dependent variables. Econometrica
1958; 26: 24–36.
Cong, R. Marginal effects for the Tobit model. Stata Techn Bull
Saarni, SI, Suvisaari, J, Sintonen, H, Pirkola, S, Koskinen, S, Aromaa, A, et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry
2007; 190: 326–32.
ten Have, M, Vollebergh, W, Bijl, R, Nolen, WA. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord
2002; 68: 203–13.
Hakkaart-van Roijen, L, Hoeijenbos, MB, Regeer, EJ, ten Have, M, Nolen, WA, Veraart, CP, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand
2004; 110: 383–92.
Davies, LM, Barnes, TR, Jones, PB, Lewis, S, Gaughran, F, Hayhurst, K, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health
2008; 11: 549–62.
Knapp, M, Windmeijer, F, Brown, J, Kontodimas, S, Tzivelekis, S, Haro, JM, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics
2008; 26: 341–58.
Prieto, L, Sacristan, JA, Hormaechea, JA, Casado, A, Badia, X, Gomez, JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin
2004; 20: 827–35.
Briggs, A, Wild, D, Lees, M, Reaney, M, Dursun, S, Parry, D, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes
2008; 6: 105.
Konig, HH, Roick, C, Angermeyer, MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry
2007; 22: 177–87.
Dean, BB, Gerner, D, Gerner, RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin
2004; 20: 139–54.
Michalak, EE, Yatham, LN, Lam, RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes
2005; 3: 72.
Depp, CA, Davis, CE, Mittal, D, Patterson, TL, Jeste, DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry
2006; 67: 215–21.
Kulkarni, J, Berk, M, Fitzgerald, PB, de Castella, AR, Montgomery, W, Kelin, K, et al. The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study. J Affect Disord
2008; 107: 135–44.
Namjoshi, MA, Buesching, DP. A review of the health-related quality of life literature in bipolar disorder. Qual Life Res
2001; 10: 105–15.
Ozer, S, Ulusahin, A, Batur, S, Kabakci, E, Saka, MC. Outcome measures of interepisode bipolar patients in a Turkish sample. Soc Psychiatry Psychiatr Epidemiol
2002; 37: 31–7.
MacQueen, GM, Young, LT, Robb, JC, Marriott, M, Cooke, RG, Joffe, RT. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand
2000; 101: 374–81.
Perala, J, Saarni, SI, Ostamo, A, Pirkola, S, Haukka, J, Harkanen, T, et al. Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. Schizophr Res
2008; 106: 337–47.
Voruganti, LN, Awad, AG, Oyewumi, LK, Cortese, L, Zirul, S, Dhawan, R. Assessing health utilities in schizophrenia. A feasibility study. Pharmacoeconomics
2000; 17: 273–86.
Fan, X, Henderson, DC, Chiang, E, Briggs, LB, Freudenreich, O, Evins, AE, et al. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res
2007; 94: 119–27.
Viertio, S, Sainio, P, Koskinen, S, Perala, J, Saarni, SI, Sihvonen, M, et al. Mobility limitations in persons with psychotic disorder: findings from a population-based survey. Soc Psychiatry Psychiatr Epidemiol
2009; 44: 325–32.
Pirkola, SP, Isometsa, E, Suvisaari, J, Aro, H, Joukamaa, M, Poikolainen, K, et al. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population. Results from the Health 2000 Study. Soc Psychiatry Psychiatr Epidemiol
2005; 40: 1–10.
Calman, KC. Quality of life in cancer patients-a hypothesis. J Med Ethics
1984; 10: 124–7.